关于在阿尔茨海默氏病中中介细胞干细胞衍生的细胞外囊泡的当前进展和未来前景
Wenjing Zhang1, Russell Uyemura2, Kun Zhong3
1College of Life Sciences, Institute of Life Science and Green Development, Hebei University, Baoding 071002, China.
Aging and disease
|January 25, 2024
概括
介质干细胞衍生的细胞外囊泡 (MSC-EVs) 为阿尔茨海默病 (AD) 提供了一个有前途的无细胞疗法. 研究探讨了MSC-EVs的机制,优化和治疗潜力,以应对这个日益增长的公共卫生挑战.
科学领域:
- 神经科学是一个神经科学.
- 再生医学是一种再生医学.
- 生物技术是生物技术.
背景情况:
- 由于人口老龄化,阿尔茨海默病 (AD) 的发病率在全球范围内不断上升,这对公共卫生构成了重大挑战.
- 目前的阿尔茨海默病治疗由于疾病复杂的发病因而受到限制.
- 细胞和基因疗法正在成为神经退行性疾病治疗的有希望的途径.
研究的目的:
- 在阿尔茨海默氏病 (AD) 治疗中审查介质干细胞衍生的细胞外囊泡 (MSC-EVs) 的应用.
- 阐明MSC-EVs在AD中发挥治疗作用的机制.
- 讨论优化MSC-EV功能及其临床翻译挑战的策略.
主要方法:
- 对AD治疗的MSC-EV近期进展的文献综述.
- 对MSC-EVs的潜在治疗机制的分析.
- 探索MSC-EV优化技术 (基因编辑,培养条件,基因修饰).
主要成果:
- MSC-EVs显示出作为阿尔茨海默氏症的无细胞疗法的潜力,提供了低免疫性和高安全性等优势.
- 各种优化策略可以提高MSC-EV的治疗疗效.
- 对于MSC-EV在AD的临床利用,仍然存在重大障碍.
结论:
- MSC-EVs代表了阿尔茨海默病的有希望的治疗策略.
- 需要进一步的研究和开发,以克服临床应用的挑战.
- 优化MSC-EV有可能改善AD治疗结果.
更多相关视频
07:03Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
2.1K
09:10A Simple Benchtop Filtration Method to Isolate Small Extracellular Vesicles from Human Mesenchymal Stem Cells
Published on: June 23, 2022
1.5K
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Intralumenal Vesicles and Multivesicular Bodies
3.5K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.5K
